hiv rt

Pol (476-484), HIV-1 RT Epitope, is a biologically active peptide representing the dominant HLA A*0201-restricted epitope within HIV-1 reverse transcriptase (RT). Spanning Pol residues 476-484, it is utilized to explore mechanisms of HIV-1 escape from cytotoxic T lymphocytes (CTL) with IV9 as the specific epitope processed and presented in HIV-1-infected cell lines.

Trovirdine (LY300046) is a thiourea non-nucleoside reverse transcriptase inhibitor.

Dapivirine (R147681) is a diarylpyrimidine non-nucleoside reverse transcriptase inhibitor.

Macrocarpal D is a HIV-RTase inhibitor. It has antibacterial activity.

Efavirenz (DMP 266) is a Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor, acting as a Non-Nucleoside Reverse Transcriptase Inhibitor, Cytochrome P450 3A Inducer, Cytochrome P450 2B6 Inducer, Cytochrome P450 2C9 Inhibitor, Cytochrome P450 2C19 Inhibitor, and Cytochrome P450 3A4 Inhibitor, classified as a Non-Nucleoside Analog.

Etravirine (R165335) is a diarylpyrimidine non-nucleoside reverse transcriptase inhibitor. Etravirine is designed to be active against HIV isolates with mutations that confer resistance to the two most commonly prescribed first-generation NNRTIs. It can bind the enzyme reverse transcriptase (RT) in multiple conformations, both for native and mutant RT, thereby blocking the enzymatic activity of RT.

4-Chloro-2-(trifluoroacetyl)aniline hydrochloride is an inhibitor of HIV-1 RT (HIV reverse transcriptase) .

EFdA-TP 3TEA is the salt form of EFdA-TP.EFdA-TP 3TEA is a nucleoside analog that is a novel, potent, and selective nucleoside reverse transcriptase (RT) inhibitor that inhibits HIV-1 reverse transcriptase by multiple mechanisms, thereby increasing its drug resistance.

4'-Ethynyl-2'-deoxyadenosine (4'-E-dA), a nucleoside reverse transcriptase (RT) inhibitor, demonstrates potent activity against drug-resistant HIV variants, with an EC50 of 98 nM in MT-4 cells for anti-HIV-1 activity.

Zapotin is a natural polyhydroxylated flavonoid that inhibits K562 cells, E. coli, and HIV-1 RT RNase H, exhibiting antioxidant, antiviral, antibacterial, anticonvulsant, anticancer, anxiolytic, antifungal, and antidepressant-like activities.

Reverse transcriptase-IN-1 is a diarylbenzopyrimidine (DABP) analogue and a potent inhibitor of HIV-1 nonnucleoside reverse transcriptase with an IC50of 13.7 nM.

Soulattrolide, a naturally occurring coumarin synthesized by Calophyllum (Calophyllaceae) rainforest tree leaves, acts as a potent inhibitor of reverse transcriptase from HIV-1 (RT-HIV-1) and exhibits activity against Mycobacterium tuberculosis.

HIV-IN-12 (Compound A1) is a dual inhibitor targeting both HIV-1 Vif and reverse transcriptase (RT). It shows potential for use in HIV infection research.

Anti-HIV agent 1 (compound 10i) is a potent antiviral agent with significant activity against HIV, showing an IC50 of 10.6 nM. It exhibits moderate or negligible inhibitory activity against RT mutant strains, while maintaining efficacy against the wild-type virus. Additionally, anti-HIV agent 1 demonstrates pronounced dual inhibitory effects on both the viral attachment and reverse transcription stages of the virus life cycle. This compound is applicable for research in HIV infection.

Stampidine can prevent the sexual transmission of HIV-1. It exhibited remarkable subnanomolar to low nanomolar in vitro antiretroviral potency against nucleoside reverse transcriptase inhibitor-resistant primary clinical HIV isolates, non-nucleoside RT-re

L-696229 is a specific inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT). L-696229 inhibited RT activity in a mutually exclusive manner with respect to either phosphonoformate or azidothymidine triphosphate and was a weak

Corydine is an alkaloid discovered in Croton echinocarpus. It can inhibit reverse transcriptase (RT) activity (IC50 = 356.8 μg/mL) and has HIV inhibitory activity.

EFdA-TP tetraammonium is an influential nucleoside reverse transcriptase (RT) inhibitor that effectively prevents RT-mediated DNA synthesis by acting as an immediate or delayed chain terminator (ICT or DCT). Additionally, EFdA-TP tetraammonium exhibits multiple mechanisms of inhibiting HIV-1 RT[1].

Tenofovir diphosphate (TFV-DP) is a competitive inhibitor of DNA polymerases, specifically targeting dATP, and functions as a substrate for the reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1)[1].

EFdA-TP, a highly potent nucleoside reverse transcriptase (RT) inhibitor, exerts its inhibitory effect on RT-catalyzed DNA synthesis through both immediate and delayed chain termination mechanisms, commonly referred to as ICT and DCT, respectively. Additionally, EFdA-TP demonstrates its efficacy in inhibiting HIV-1 RT through multiple pathways.

HIV-1 inhibitor-47 is a potent HIV-1 reverse transcriptase (RT) inhibitor. It suppresses viral replication by blocking RNA-to-DNA conversion, used for developing new therapies against drug-resistant HIV strains.

HIV-1 inhibitor-30 (compound 10i) is a potent inhibitor of HIV-1, specifically targeting the RT DNA polymerase enzyme, showing strong antiretroviral activity with an EC50 value of 40 nM and an IC50 value of 80 nM. Moreover, it demonstrates significant effectiveness against seven NNRTI-resistant strains of HIV-1 (RT-K103N; RT-Y181C; RT-K103N, Y181C; RT-L100I, K103N; RT-Y188L; RT-K103N, G190A; RT-K103N, V108I), with IC50 values from 0.04 to 1.42 μM. This compound holds potential for AIDS research [1].

HIV-1 inhibitor-42 (compound 5b) is a potent inhibitor of HIV-1 with an IC50 of 0.06 μM. It inhibits HIV-1 RT RNA-dependent DNA polymerase with an IC50 of 0.518 μM and DNA-dependent DNA polymerase with an IC50 of 0.072 μM.

HIV-1 inhibitor-24 (compound S-12a) is a potent inhibitor of HIV-1 reverse transcription (HIV-1 RT) with an IC50 of 9.5 nM. It exhibits a high antiviral effect on wild-type HIV-1, showing an EC50 value of 1.6 nM and low cytotoxicity (CC50 on MT-4 cells). HIV-1 inhibitor-24 was well tolerated in mice at a dose of 2 g/kg and demonstrated a significant cardiovascular safety profile.